AllianzIM U.S. Large Cap Buffer10 Sep ETF SEPT 深 沪
已收盘 10-03 16:00:00 美东时间
34.5037
+0.014
+0.04%
华盛通- 最 高34.61
- 今 开34.6099
- 成交量 1.03万股
- 最 低 34.46
- 昨 收 34.4897
- 总市值 1897.70万
- 52周最高 34.61
- 市盈率 静 --
- 换手率 1.88%
- 52周最低 25.54
- 委 比 -60.00%
- 总股本 55.00万
- 历史最高 34.61
- 量 比 1.02
- 振 幅 0.43%
- 历史最低 23.42
- 每 手 1
- 风险率 1.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Flywire Corporation (FLYW) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Sept. 19, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Flywire Corporation ("Flywire" or the "Company") (NASDAQ: FLYW) h...
09-20 03:51
TETRA TECHNOLOGIES, INC. INVESTOR DAY SCHEDULED ON SEPTEMBER 25, 2025, AT THE NEW YORK STOCK EXCHANGE
THE WOODLANDS, Texas, Sept. 17, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) will be hosting an Investor Day on Thursday, September 25, 2025, at 8:30AM...
09-18 03:52
Septerna to Participate in Upcoming Investor Conferences
Septerna, Inc., a clinical-stage biotech company focused on GPCR drug discovery, announced its participation in two upcoming investor conferences in September: the Cantor Global Healthcare Conference 2025 on September 3, 2025, and the 2025 Wells Fargo Healthcare Conference on September 5, 2025. Live webcasts and replays of the presentations will be available on the company’s website. Septerna specializes in advancing GPCR therapies using its prop...
08-27 12:00
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-631, a novel oral treatment targeting chronic spontaneous urticaria and mast cell-driven diseases. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631 in healthy volunteers. As a selective negative allosteric modulator of MRGPRX2, SEP-631 inhibits mast cell activation and degranulation, offering potential relief for millions affected b...
08-21 12:00
RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) have opp...
08-15 00:00
Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) have oppo...
07-29 00:00
Septerna to Present at Jefferies Global Healthcare Conference
Septerna, Inc., a biotechnology company focused on GPCR drug discovery, announced that its CEO, Jeffrey Finer, will present at the Jefferies Global Healthcare Conference on June 5, 2025. A live webcast of the presentation will be available on the company’s website and will be archived for at least 30 days. Septerna’s proprietary Native Complex Platform™ enables the discovery of oral small molecule product candidates targeting endocrinology, immun...
05-29 12:00
SQM REPORTS EARNINGS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024
Highlights SQM reported total revenues for the nine months ended September 30, 2024 of US$3,455.0 million compared to total revenues of US$6,155.9 million for the same period last year. Ne...
2024-11-20 21:00
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
– 14% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® – – 2024 total revenue guidance affirmed at $4.0 to $4.1 billion – – Zanidatamab 2L BTC...
2024-11-07 05:05
NACCO INDUSTRIES ANNOUNCES THIRD QUARTER 2024 RESULTS
Consolidated Q3 2024 Highlights: Operating profit of $19.7 million compared with Q3 2023 $6.3 million operating loss Q3 2024 includes $13.6 million of business interruption insurance income ...
2024-10-31 04:52
